SGL Investment Advisors Inc. Takes Position in Danaher Co. (NYSE:DHR)

SGL Investment Advisors Inc. bought a new position in Danaher Co. (NYSE:DHR - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 14,464 shares of the conglomerate's stock, valued at approximately $4,021,000. Danaher accounts for about 2.0% of SGL Investment Advisors Inc.'s holdings, making the stock its 21st largest holding.

Other institutional investors and hedge funds have also modified their holdings of the company. nVerses Capital LLC purchased a new position in Danaher during the 2nd quarter valued at about $25,000. CarsonAllaria Wealth Management Ltd. purchased a new position in Danaher during the second quarter valued at approximately $25,000. Teachers Insurance & Annuity Association of America purchased a new stake in Danaher in the 3rd quarter worth approximately $39,000. MidAtlantic Capital Management Inc. acquired a new stake in shares of Danaher during the 3rd quarter valued at $40,000. Finally, FSA Wealth Management LLC purchased a new position in shares of Danaher during the 3rd quarter valued at $50,000. Hedge funds and other institutional investors own 79.05% of the company's stock.

Danaher Stock Performance

Shares of NYSE:DHR traded up $5.43 on Monday, hitting $235.55. 1,477,481 shares of the company were exchanged, compared to its average volume of 2,773,867. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The company's 50 day moving average price is $250.76 and its two-hundred day moving average price is $258.32. Danaher Co. has a one year low of $217.96 and a one year high of $281.70. The firm has a market capitalization of $170.13 billion, a price-to-earnings ratio of 43.92, a PEG ratio of 4.23 and a beta of 0.83.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping analysts' consensus estimates of $1.57 by $0.14. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The company's quarterly revenue was up 3.1% on a year-over-year basis. During the same quarter last year, the company earned $2.02 EPS. Research analysts expect that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.46%. The ex-dividend date of this dividend was Friday, September 27th. Danaher's dividend payout ratio is 20.61%.

Wall Street Analyst Weigh In

DHR has been the subject of a number of research reports. Barclays reduced their price objective on Danaher from $285.00 to $275.00 and set an "equal weight" rating for the company in a research report on Wednesday, October 23rd. Stifel Nicolaus lifted their target price on shares of Danaher from $250.00 to $265.00 and gave the company a "hold" rating in a research note on Wednesday, October 23rd. UBS Group dropped their price target on shares of Danaher from $309.00 to $305.00 and set a "buy" rating on the stock in a research note on Wednesday, October 23rd. Royal Bank of Canada reduced their price objective on shares of Danaher from $333.00 to $311.00 and set an "outperform" rating for the company in a research note on Wednesday, October 23rd. Finally, Raymond James decreased their price objective on shares of Danaher from $310.00 to $300.00 and set an "outperform" rating for the company in a report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $287.16.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.